---
title: "Phenoxybenzamine - Pheochromocytoma"
sidebar: mydoc_sidebar
permalink: db06718-mesh-d010673-1.html
toc: false 
---


Path ID: `DB06718_MESH_D010673_1`
{% include image.html url="images/db06718-mesh-d010673-1.png" file="db06718-mesh-d010673-1.png" alt="db06718-mesh-d010673-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D010643">MESH:D010643 </a> | phenoxybenzamine | Drug |
| <a href="https://identifiers.org/UniProt:P35348">UniProt:P35348 </a> | Alpha-1A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P08913">UniProt:P08913 </a> | Alpha-2A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18825">UniProt:P18825 </a> | Alpha-2C adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P25100">UniProt:P25100 </a> | Alpha-1D adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18089">UniProt:P18089 </a> | Alpha-2B adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P35368">UniProt:P35368 </a> | Alpha-1B adrenergic receptor | Protein |
| <a href="https://identifiers.org/GO:0042310">GO:0042310 </a> | vasoconstriction | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D014655">MESH:D014655 </a> | Vascular Resistance | BiologicalProcess |
| <a href="https://identifiers.org/HP:0002640">HP:0002640 </a> | Hypertension associated with pheochromocytoma | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D010673">MESH:D010673 </a> | Pheochromocytoma | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Phenoxybenzamine | DECREASES ACTIVITY OF | Alpha-1A Adrenergic Receptor |
| Phenoxybenzamine | DECREASES ACTIVITY OF | Alpha-2A Adrenergic Receptor |
| Phenoxybenzamine | DECREASES ACTIVITY OF | Alpha-2C Adrenergic Receptor |
| Phenoxybenzamine | DECREASES ACTIVITY OF | Alpha-1D Adrenergic Receptor |
| Phenoxybenzamine | DECREASES ACTIVITY OF | Alpha-1B Adrenergic Receptor |
| Phenoxybenzamine | DECREASES ACTIVITY OF | Alpha-2B Adrenergic Receptor |
| Alpha-1A Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-2A Adrenergic Receptor | REGULATES | Vasoconstriction |
| Alpha-2C Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-1D Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-1B Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Alpha-2B Adrenergic Receptor | POSITIVELY REGULATES | Vasoconstriction |
| Vasoconstriction | POSITIVELY CORRELATED WITH | Vascular Resistance |
| Vascular Resistance | POSITIVELY CORRELATED WITH | Hypertension Associated With Pheochromocytoma |
| Hypertension Associated With Pheochromocytoma | MANIFESTATION OF | Pheochromocytoma |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00925#mechanism-of-action](https://go.drugbank.com/drugs/DB00925#mechanism-of-action)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL753/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL753/)
  - [https://en.wikipedia.org/wiki/Alpha_blocker#Hypertension](https://en.wikipedia.org/wiki/Alpha_blocker#Hypertension)
  - [https://en.wikipedia.org/wiki/Phenoxybenzamine#Pharmacology](https://en.wikipedia.org/wiki/Phenoxybenzamine#Pharmacology)
  - [https://en.wikipedia.org/wiki/Pheochromocytoma#Alpha_blockade](https://en.wikipedia.org/wiki/Pheochromocytoma#Alpha_blockade)
